Targeting minimal residual disease: a path to cure?

@article{Luskin2018TargetingMR,
  title={Targeting minimal residual disease: a path to cure?},
  author={Marlise R. Luskin and Mark A. Murakami and Scott R. Manalis and David M. Weinstock},
  journal={Nature Reviews Cancer},
  year={2018},
  volume={18},
  pages={255-263}
}
Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests… CONTINUE READING

From This Paper

Figures and tables from this paper.

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 83 references

2017

Armitage, J. O. The aggressive peripheral T-cell lymphomas
Am. J. Hematol. 92, 706–715 • 2017

Long-term follow-up of the French stop imatinib (STIM1) Study in patients with chronic myeloid leukemia

G Etienne
J. Clin. Oncol • 2017

Osimertinib benefit in EGFRmutant NSCLC patients with T 790 Mmutation detected by circulating tumour DNA

A.
Ann . Oncol . • 2017

Similar Papers

Loading similar papers…